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Abstract
Outcomes of kidney transplant (KT) patients with pre-transplant pulmonary hypertension (PH) are poorly understood. PH
patients are often considered high risk and excluded from KT. We investigated the association of pre-transplant PH with KT
recipient’s outcomes. A single-center, retrospective study that reviewed all patients transplanted from 2010 to 2016, who
had a transthoracic echocardiogram (TTE) before KT and at least one TTE post-KT. The TTE closest to the KT was used for
analyses. PH is defined as pulmonary artery systolic pressure (PASP) ≥ 40 mm Hg. Of 204 patients, 61 had PASP ≥ 40 mm Hg
(with PH) and 143 had PASP < 40 mm Hg (without PH) prior to KT. No statistically significant differences existed between
the two groups in baseline demographics, renal failure etiologies, dialysis access type, and cardiovascular risk factors. The
mean difference in pre-KT PASP was 18.1 ± 7 mm Hg (P < 0.001). Patients with PH had a statistically significant decrease
in PASP post-KT compared to the patients without PH with a mean change of -7.03 ± 12.28 mm Hg vs. + 3.96 ± 11.98 mm
Hg (p < 0.001), respectively. Moderate mitral and moderate-severe tricuspid regurgitation were the only factors found to be
independently associated with PH (p = 0.001) on multivariable analysis. No statistically significant difference was notable
in patient survival, graft function, and creatinine post-KT in both groups. PH pre-KT particularly mild-moderate PH did not
adversely affect intermediate (90-day) and long-term allograft and patient survival. Patients with mild-moderate PH should
not be excluded from KT.
Keywords Pulmonary hypertension · End-stage kidney disease · Kidney transplant · Survival
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Prior presentation: The work was presented as a poster at the
Michigan Chapter of the American College of Cardiology 30th
Annual Conference, Detroit, MI, October 26-27, 2018.
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Pulmonary hypertension (PH) is commonly encountered in
patients with underlying chronic kidney disease and endstage kidney disease (ESKD). Several observations have
reported an association between PH and increased morbidity and mortality in this population [1]. The studies on the
prevalence of PH in kidney disease is variable with reports
ranging from 27 to 58% in ESKD patients on hemodialysis
to 17%–32% in patients undergoing evaluation for a kidney
transplant (KT) [2–5]. This variability is in part related to
different definitions used for PH, but also the variety of contributing elements to PH plays a role, with higher prevalence
reported with older age, longer duration on hemodialysis [6],
and the presence of cardiovascular comorbidities [1].
Transthoracic echocardiography (TTE) is the most common diagnostic imaging performed as part of the pre-transplant evaluation of patients with chronic kidney disease and
ESKD. It is a versatile, readily available test with a wealth
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of information on cardiac structure and function. It is also
the recommended first-line test to noninvasively assess left
ventricular (LV) function and estimate pulmonary artery
systolic pressure (PASP) for evaluating PH in pre-transplant
candidates by leading societal guidelines [7].
Despite KT being the final logical solution for ESKD
patients, some studies have shown that moderate to severe
PH is associated with worse overall post-transplant outcomes, perioperative complications as well as worse graft
survival [1, 8–12]. However, other studies have shown that
PH may improve post-KT and may not affect post-KT graft
and patient survival [13–15]. Thus overall, PH continues to
pose a dilemma with regards to KT listing and outcomes.
We have previously reported our experience in patients
with LV dysfunction undergoing KT and demonstrated
that patients with preexisting LV dysfunction should not
be excluded from listing for KT. A substantial number of
these patients had improvement of LV function post-KT
[16]. Given that PH is commonly associated with chronic
kidney disease and ESKD with or without LV dysfunction,
it remains a challenge for pre-KT assessment and transplant
listing. Thus, we conducted a retrospective single-center
study at our institution to study our experience with PH and
KT focusing on graft survival and mortality at our center.

Materials and methods
Study population
We conducted a retrospective chart review at our center from
January 2010 until April 2016 with a principal diagnosis of
ESKD who underwent KT and had a TTE pre- and post-KT.
PH was defined as PASP ≥ 40 mm Hg derived from pre-KT
TTE. The maximum tricuspid regurgitation flow obtained
by continuous-wave Doppler examination was used in the
modified Bernoulli equation to estimate PASP equal to
4V2 + plus right atrial pressure [17].

Data collection
Henry Ford Health System Institutional Review Board
reviewed and approved the study protocol (IRB no: 12248).
Data were collected on patient demographics, medical
comorbidities, valvular heart disease, systolic and diastolic
heart failure, etiology of ESKD, donor type, and type of
dialysis access. TTE specific data included PASP, ejection
fraction, and valvular pathology, data were collected through
review of clinical reports. We stratified patients into two
groups according to the PASP (≥ or < 40 mm Hg). The TTE
closest to the KT was used to determine pre-KT PASP. PostKT PASP was determined from the first available TTE after
transplant. If patients had a second TTE post-KT, data were
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collected from that as well. A univariate comparison on KT
patients with and without PH was performed. Additionally,
a subgroup analysis of patients with PH who had a drop
in PASP ≥ 10 mm Hg after KT on the first TTE compared
to those who did not was reported. Finally, we evaluated
patients’ outcomes and graft function according to follow-up
documentation in the medical record.

Statistical analysis
The sample of patients is described using counts and percentages for categorical variables and using means, standard
deviations, medians, minimums, and maximums for continuous variables. Univariate two-group comparisons for
continuous and categorical variables were carried out using
two-group t-tests and chi-square tests, respectively. Multivariable logistic regression models were used to identify
independent predictors of pre-KT PH, and results are presented using adjusted odds ratios and their 95% CIs. Models
were checked for multicollinearity using correlation coefficients, variance inflation factors, eigenvalues, and condition indices, and no issues were detected. Kaplan–Meier
survival estimates were used to determine patient survival
with median survival time, calculated as the time at which
survival probability reaches 0.50. Statistical significance was
set at p < 0.05. All analyses are performed using SAS 9.4
(SAS Institute Inc, Cary, NC).

Results
Of the 204 patients (113 male and 91 female), 61 (29.9%)
were identified to have pre-KT PH. A summary of the analyzed patients’ characteristics is listed in (Table 1).
There was no statistically significant difference between
the two groups (PASP ≥ or < 40 mm Hg) in terms of demographics, body mass index, cardiovascular risk factors, etiology of ESKD, transplant type, prevalence of coronary artery
disease, systolic and diastolic heart failure, peripheral artery
disease, venous disease, or asthma. Patients with PH noted
to have a statistically significant difference in valvular heart
disease (p < 0.001), specifically moderate mitral regurgitation (p = 0.01) and moderate to severe tricuspid regurgitation
(p = 0.001). On multivariate analysis, moderate to severe tricuspid regurgitation was the only factor found to be independently associated with PH (p = 0.001) (Table 2).
The mean pre-KT PASP was 35.20 ± 10.7 mm Hg in
the entire study group; the group with PH showed a mean
PASP of 47.8 ± 7.7 mm Hg compared to 29.7 ± 6.3 mm
Hg in the group without PH (p < 0.001). The distribution
of PASP in each group is illustrated in (Fig. 1). A significant decrease in PASP post-KT ≥ 10 mm Hg was noted
in 21.3% (n = 43). Patients in the group with PH had a
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Table 1  Demographic data
Characteristic

N (%) (N = 204)

Gender
Male
Race
Caucasian
African American
Other
Kidney donor
Deceased
Living
Etiology of ESKD
Hypertension
Diabetes mellitus
Glomerulonephritis
Polycystic kidney disease
Interstitial nephritis
Hepatorenal syndrome
Retransplant
Other
Peripheral vascular occlusive disease
Coronary artery disease
Hypertension
Diabetes mellitus
Cardiomyopathy
Diastolic heart failure
Systolic heart failure
Asthma

113 (55.5)
69 (34.0)
120 (59.1)
15 (6.9)
130 (64.0)
73 (35.9)
70 (34.3)
64 (31.4)
13 (6.4)
12 (5.9)
6 (2.9)
9 (4.4)
10 (4.9)
19 (9.3)
33 (16.3)
61 (29.9)
192 (94.6)
110 (54.2)
61 (29.9)
12 (5.9)
25 (12.3)
1 (0.5)

ESKD, end-stage kidney disease

Table 2  Multivariable model of pre-transplant pulmonary hypertension
Variable
Valvular heart disease (all/any)
Moderate/Severe MR
Moderate/Severe TR
Diastolic heart failure
Systolic heart failure
Diabetes mellitus
AVF or AVG

OR (95% CI)
0.39 (0.04–3.50)
4.87 (0.52–46.10)
40.67 (4.21–393.18)
2.51 (0.69–9.11)
0.35 (0.10–1.28)
1.23 (0.60–2.50)
0.82 (0.41–1.63)

P Value
0.397
0.167
0.001
0.160
0.112
0.573
0.572

AVF arteriovenous fistula, AVG arteriovenous graft, MR mitral regurgitation, OR odds ratio, TR tricuspid regurgitation

statistically significant decrease in their PASP, with 47.5%
(n = 29) of patients dropping PASP by at least 10 mm Hg
after transplant compared to 9.9% (n = 14) of patients
in the group without PH (p < 0.001), and these changes
persisted on second follow-up TTE (p < 0.001) (Table 3).

Figure 2 is showing an example of the change in a patient’s
tricuspid regurgitation signal from pre- to post-KT.
The mean time interval from pre-KT TTE to transplant was 13.62 ± 13.9 months (without PH) vs.
12.55 ± 12.5 months (with PH) (p = 0.606). Time from the
KT to first TTE was 23.08 ± 26.53 months (without PH) vs.
21.91 ± 26.29 months (with PH) (p = 0.773), and for the KT
to second TTE it was 39.32 ± 29.62 months (without PH)
vs. 33.86 ± 24.75 months (with PH) (p = 0.371). The median
ejection fraction was 53% ± 9.60%, with no statistically significant changes after KT documented between the groups
on the first and second TTE. (Fig. 3) depicts the difference
in left ventricular size pre- and post-KT in a patient with
pre-KT PH.
A subgroup analysis was performed among a subset of
pre-KT PH patients who had a significant decrease (PASP
drop ≥ 10 mm Hg) in their PASP on the first post-KT TTE.
These patients had a higher pre-KT PASP with a mean
difference of + 4.2 ± 0.14 mm Hg (p = 0.029), and more
significant post-KT PASP drop with a mean difference of
-14.92 ± 4.5 mm Hg (p < 0.001). They also had a longer
duration of dialysis with a mean difference + 0.95 ± 1.3 years
(p = 0.036), and a more prevalent arteriovenous graft dialysis
access (p = 0.009) despite no differences in valvular heart
disease.
The mean creatinine post-KT for the entire group was
2.01 ± 1.63 mg/dL, graft failure happened in 26.5% (n = 54)
with no significant difference in graft function, or graft failure noted between the groups or the subgroup with PASP
drop post-KT.
The mean follow-up period was 77.9 ± 36.12 months,
with no significant difference between the groups. Overall
mortality was 32.8% (n = 67) at the end of the follow-up
period, with 30.7% mortality in the group without PH versus
37.7% in the group with PH (p = 0.334) (Fig. 4).

Discussion
The main findings of this study can be summarized as follows: First, PH is commonly encountered in pre-KT evaluation, with a 29.9% prevalence in this study population;
second, a substantial number of patients with PH (47.5%)
dropped their PASP significant post-KT; and third, mild to
moderate Pre-KT PH had no adverse effects on overall survival or graft loss post-KT regardless of the severity of PH
or the duration of dialysis.

Cardiovascular factors
The definition of PH varies in the literature, with most defining it as PASP ≥ 35 or 40 mm Hg. Our analysis showed a
comparable prevalence of pre-KT PH to previous literature
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Fig. 1  Boxplot of the pulmonary artery systolic pressure in
groups with and without PH

Table 3  PASP comparison between groups with and without PH
Covariate (mm Hg)

Statistics

PH
No

Pre-KT PASP
Post-KT PASP TTE 1
Drop in PASP from pre-KT to post-KT TTE 1
Post-KT PASP TTE 2
Drop in PASP from post-TTE 1 to 2
Drop in PASP from pre-KT to post-KT TTE 2

Mean ± SD
Mean ± SD (N)
Mean ± SD (N)

29.73 ± 6.33
33.59 ± 12.35 (143)
3.96 ± 11.98
36.3 ± 11.23 (60)
1.33 ± 13.68
5.95 ± 12.52

Parametric P value
Yes
47.84 ± 7.77
40.8 ± 13.25 (61)
− 7.03 ± 12.28
43.27 ± 14.72 (33)
2.55 ± 15.96
− 5.03 ± 14.06

< 0.001
< 0.001
< 0.001
0.012
0.701
< 0.001

KT kidney transplant, PASP pulmonary artery systolic pressure, PH pulmonary hypertension, SD standard deviation, TTE trans-thoracic
echocardiogram

Fig. 2  Tricuspid regurgitation velocity and gradient pre-KT (left) and post-KT (right) in a patient with pre-KT PH; illustrating a drop of TR peak
gradient by 16.4 mm Hg

[12, 14]. Several studies demonstrated a link between PH
and mortality, with two meta-analyses finding a remarkable
association between PH and cardiovascular event rate and
increased mortality in chronic kidney disease and ESKD
patients, with risks being proportional to the stage of chronic
kidney disease [1, 18]. While some studies suggested that
PH is an independent risk factor for all-cause mortality after
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adjusting for cardiovascular variables [19], other studies did
not confirm PH and worse outcomes post KT. Rather LV
dysfunction and race were factors associated with worse
outcome [15].
Hypertension and diabetes accounted for 65% of ESKD
etiologies in our study. Studies have linked diabetes to PH
[20], worse graft survival [21], and lower patient survival
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Fig. 3  Left ventricular size pre-KT (left) and post-KT (right) in a patient with pre-KT PH
Fig. 4  Kaplan–Meier curves
of overall survival by a group.
The difference in survival is not
statistically significantly different (p = 0.220). PH pulmonary
hypertension

post-KT [22]. However, the last finding is challenged with
better post-KT glycemic control and accountancy of other
cardiovascular risk factors. Our study groups had similar
cardiovascular risk factors distribution in both the main
groups and the subgroups analysis.
In line with our previous finding, pre-KT LV dysfunction does not affect graft failure or survival of KT recipients
[16]. Another study documented improvements in LV TTE
parameters post-KT [13]. In contrast, systolic dysfunction
in KT recipients with pre-KT PH was found to be associated
with worse graft outcomes [15]. Our findings showed LV
systolic and diastolic dysfunction were evenly distributed
in both groups and did not predict pre-transplant PH in our
evaluation.

Echocardiography
Like most transplant centers, right heart catheterization
was not the standard of care in our pre-KT evaluation. The
selection of patients who need catheterization to evaluate PH
usually involves a multidisciplinary decision from cardiology and pulmonology. The use of TTE to estimate PASP
has been described in a meta-analysis examining 29 studies. TTE had a sensitivity and specificity of 83% (95% CI
73%–90%) and 72% (95% CI 53%–85%), respectively, to
diagnose PH, with a correlation coefficient of 0.70 when
compared to right heart catheterization [23]. Other observations have suggested that PASP > 35 mm Hg is abnormal
regardless of the fluid status, reasoning that TTE possibly
underestimates and rarely overestimates the value of PASP
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[11]. It is worth noting that the PASP changes reported on
our first post-KT TTE were persistent on a second post-KT
TTE.

Dialysis duration and access
There was an association between longer duration on hemodialysis with both the severity of PH and ventricular dysfunction [12, 13, 20]. Concordantly, the presence of arteriovenous fistula access correlated with a higher PASP [20, 24].
In one report it was pointed out that underlying functional
abnormalities of the pulmonary circulation likely contribute
to the inability to accommodate the increase in cardiac output related to the arteriovenous fistula leading to PH [13].
Although our groups did not differ in the duration of
dialysis or vascular access, we noticed a longer duration of
dialysis in patients with PH who dropped their PASP significantly ≥ 10 mm Hg post-KT on the subgroup analysis.
This significant drop was not related to dialysis access closure after KT and may have been related to fluid overload
status seen in patients with ESKD. Equally important, the

outcomes of these patients were the same at the end of the
follow-up period.

Graft and patient survival
Prior studies have suggested that Pre-KT PH significantly
increased the risk of delayed graft function and early graft
dysfunction in deceased donor recipients. Yet, this effect
was not seen in living donor recipients [11, 25]. Other
evidence proposed the association of severe pre-KT PH
(PASP > 50 mm Hg) with worse post-transplant survival
[12]. Our study found a more significant drop in PASP in
patients with worse pre-KT PH. Two-thirds of our patients
received a KT from a deceased donor and no disparity in
survival, graft dysfunction or follow-up creatinine was noted
in our groups.
A summary of the existing evidence on the outcome of
KT recipients with pre-KT PH is listed in Table 4.

Limitations
The major limitation of the study pertains to the retrospective single-center setup. The study populations were

Table 4  Retrospective studies on the association of pre-KT PH and post-KT outcomes
Study

Studied population

Outcomes of transplanted patients with PH

Issa et al. [12]

215 KT recipients 32% with PH, defined by pre-transplant RVSP > 35 mm Hg on TTE

Zlotnick et al. [11]

55 KT recipients 38% with PH, defined by
PASP > 35 mm Hg on TTE

RVSP of 50 mm Hg or greater was independently associated with an increased risk of post-transplant death
Time on dialysis was the strongest correlate of an elevated
RVSP
Early graft dysfunction was more common in deceased
kidney recipients with PH, specifically if PASP > 45 mm
Hg
PASP decreased significantly by 12 months post-transplantation, with a reduction in PH in 14.3% of the study
population (P = 0.01)
Two groups according to PASP with cut-off of 35 mm
Hg. Group with PASP ≥ 35 mm Hg showed a significant decrease in survival (hazard ratio 1.98; 95% CI
1.042–3.74, P = 0.037) after adjustment for comorbidities. Graft failure assessed by Kaplan–Meier analysis
showed graft failure probabilities for both PASP groups
were increased at similar rates, “deceased subjects were
included in this analysis” (hazard ratio 0.34; 95% CI
0.12–1.01, P = 0.05)
Mild and moderate pre-KT PH does not affect post-KT
mortality and graft loss at 4 years. However, it was
associated with post-KT decline in estimated glomerular
filtration rate at first and second years
Reduced patient and graft survival were seen in recipients with pre-transplant PH. However, this was not
attributable to PH, but rather to age, black race and left
ventricular systolic dysfunction

Casas-Aparicio et al. [13] 35 KT recipients 48.6% with PH, defined by
PASP ≥ 40 mm Hg on TTE
Jarmi et al. [25]

363 KT recipients, 36.08% with PH, PASP measured
through RHC at time of transplantation

Wang et al. [14]

192 KT recipients, 26% with PH, defined by
PASP ≥ 37 mm Hg on TTE

Obi et al. [15]

773 KT recipients, 18% with PH, defined by
PASP ≥ 35 mm Hg on TTE

KT kidney transplant, PASP pulmonary artery systolic pressure, PH pulmonary hypertension, RHC right heart catheterization, RVSP right ventricular systolic pressure, TTE trans-thoracic echocardiogram
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predominantly African American, limiting its generalizability. Patients with PH who were excluded from transplant on initial evaluation were not included in the analysis, these patients might have been sicker compared to
PH patients who underwent KT. Given our sample mostly
involved patients with mild-moderate PH, our current
findings are difficult to extend to patients with severe PH
with “PASP > 60 mm Hg”. The diagnosis of PH and its
contributors were not directly validated by right heart
catheterization. The study population with PH may have
had combined pre and post capillary PH which was not
separately evaluated and could be associated with worse
prognosis when associated with right ventricular dysfunction. At the time of study routine detailed analysis of right
heart quantitative parameters were not done consistently
for PH patients which prevents us from factoring in right
heart function which we acknowledge as an important
variable. Utilizing TTE’s clinical report impact the accuracy of the PASP measurements, as the clinicians were
neither blinded nor followed a standard protocol during
measurement. Besides, the timing of PASP measurement
pre-KT in relation to volume status was lacking and was
not standardized. Furthermore, the level of hemoglobin
level and the presence of AVF might have affected PASP
measurement, making the flow state a challenging confounding variable which was not formally evaluated by
right heart catheterization given the retrospective nature of
study. However since 2015 we have instituted right heart
protocol echocardiography doing detailed analysis of right
heart function but is not applicable to this study population. Finally, the role of endothelial-derived molecules,
including endothelin-1, thromboxane, and nitric oxide,
was not analyzed in this study.

Conclusion
Despite prior evidence showing that PH is a worrisome
sign in recipients of a KT, this study showed no impact on
post-transplant survival and graft function. Based on these
findings, patients with preexisting mild to moderate PH
should not be excluded from KT evaluation. Optimization
of cardiovascular care, proper pre-transplant PH evaluation, and perioperative management team collaboration,
should better support triaging PH patients.
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